| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Boris Birmaher | Q63214888 |
| P2093 | author name string | Soledad Romero | |
| Khrista Boylan | |||
| P2860 | cites work | Study 329 | Q20746326 |
| Psychological and/or educational interventions for the prevention of depression in children and adolescents | Q24247244 | ||
| A rating scale for depression | Q24564540 | ||
| Efficacy of interpersonal psychotherapy for depressed adolescents | Q28198888 | ||
| A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features | Q28269991 | ||
| A children's global assessment scale (CGAS) | Q28271291 | ||
| Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial | Q32041846 | ||
| Methods of adolescent suicide prevention | Q33540369 | ||
| The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder | Q33772748 | ||
| Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. | Q33994367 | ||
| Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder | Q34005047 | ||
| Treatment options in the management of adolescent depression | Q34130174 | ||
| Can recovery from depression be achieved? | Q34422020 | ||
| Practice parameter for use of electroconvulsive therapy with adolescents | Q34552856 | ||
| Childhood and adolescent depression: a review of the past 10 years. Part I. | Q34736609 | ||
| Childhood and adolescent depression: a review of the past 10 years. Part II. | Q34737049 | ||
| Course and outcome of child and adolescent major depressive disorder | Q34834286 | ||
| Transcranial magnetic stimulation in the treatment of depression | Q35120020 | ||
| Predictors of response to treatment in children and adolescents with mood disorders | Q35142081 | ||
| Vagus nerve stimulation: mood and cognitive effects | Q35630248 | ||
| The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics | Q35988709 | ||
| Treatment guidelines for children and adolescents with bipolar disorder | Q36052032 | ||
| Review of the efficacy and safety of antidepressants in youth depression | Q36171352 | ||
| Pharmacologic management of difficult-to-treat depression in clinical practice | Q36222690 | ||
| Continuation and maintenance therapy of early-onset major depressive disorder | Q36238434 | ||
| Antidepressant-induced manic conversion: a developmentally informed synthesis of the literature | Q36248038 | ||
| The risks and benefits of antidepressant treatment for youth depression | Q36276293 | ||
| Effects of psychotherapy for depression in children and adolescents: a meta-analysis | Q36293430 | ||
| ACNP Task Force report on SSRIs and suicidal behavior in youth | Q36327813 | ||
| The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression | Q36428441 | ||
| Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial | Q39456259 | ||
| First onset versus recurrence of depression: differential processes of psychosocial risk | Q39516417 | ||
| Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence | Q40770549 | ||
| Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents | Q41496973 | ||
| Continuity of depression during the transition to adulthood: a 5-year longitudinal study of young women | Q41679147 | ||
| Outcome at 6 months for 50 adolescents with major depression treated in a health maintenance organization | Q41702171 | ||
| A family study of major depressive disorder in a community sample of adolescents | Q43427814 | ||
| The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine | Q43542553 | ||
| Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression | Q43565910 | ||
| Mood disorders in children and adolescents: psychopharmacological treatment | Q43656806 | ||
| Fluoxetine for the treatment of childhood anxiety disorders | Q44370632 | ||
| Age effects on antidepressant-induced manic conversion | Q45003904 | ||
| Antidepressants and pediatric depression--the risk of doing nothing | Q45106193 | ||
| Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study | Q45122504 | ||
| Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants | Q46055681 | ||
| Psychosocial risk factors of child and adolescent completed suicide | Q46180568 | ||
| Steady-state pharmacokinetics of bupropion SR in juvenile patients | Q46396062 | ||
| Suicidality in pediatric patients treated with antidepressant drugs | Q46977975 | ||
| Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression | Q47349331 | ||
| The clinical picture of major depression in children and adolescents | Q47356207 | ||
| Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial | Q48779782 | ||
| The effect of concomitant disorders in childhood depression on predicting treatment response | Q48931501 | ||
| A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. | Q50924850 | ||
| Fluoxetine in child and adolescent depression: acute and maintenance treatment. | Q51097644 | ||
| A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. | Q51940276 | ||
| A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP). | Q51941426 | ||
| Children with prepubertal-onset major depressive disorder and anxiety grown up. | Q51947556 | ||
| Modification of DSM-IV criteria for depressed preschool children. | Q51948478 | ||
| Disentangling disinhibition. | Q52182437 | ||
| Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up. | Q52231819 | ||
| Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. | Q53281125 | ||
| Paroxetine pharmacokinetics in depressed children and adolescents. | Q53927447 | ||
| Suicide risk during antidepressant treatment. | Q55041518 | ||
| The Serotonin Syndrome | Q55871784 | ||
| Screening for Depression in Mothers Bringing Their Offspring for Evaluation or Treatment of Depression | Q57150604 | ||
| Depressed Adolescents Grown Up | Q57150621 | ||
| The Maudsley long-term follow-up of child and adolescent depression | Q59621512 | ||
| Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents | Q61948545 | ||
| MAOIs in adolescent major depression unresponsive to tricyclic antidepressants | Q67980751 | ||
| Lithium Antidepressant Augmentation in TCA-refractory Depression in Adolescents | Q68392640 | ||
| A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants | Q68535440 | ||
| Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation | Q70392247 | ||
| Suicidal behaviors and childhood-onset depressive disorders: a longitudinal investigation | Q70550378 | ||
| Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients | Q71573717 | ||
| Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children | Q72000594 | ||
| Treating anxiety disorders in children: results of a randomized clinical trial | Q72068976 | ||
| A psychoeducational program for families of affectively ill children and adolescents | Q72854510 | ||
| Short-term outcome of major depression: I. Comorbidity and severity at presentation as predictors of persistent disorder | Q73069850 | ||
| Venlafaxine in the treatment of children and adolescents with major depression | Q73303455 | ||
| Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder | Q73347318 | ||
| A controlled trial of light therapy for the treatment of pediatric seasonal affective disorder | Q73414665 | ||
| Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association | Q73682867 | ||
| Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy | Q74459413 | ||
| Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression | Q74509376 | ||
| Gender and the course of major depressive disorder through adolescence in clinically referred youngsters | Q74511995 | ||
| Clinical presentation and course of depression in youth: does onset in childhood differ from onset in adolescence? | Q75201918 | ||
| Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. AACAP | Q77454969 | ||
| First onset of depressive or anxiety disorders predicted by the longitudinal course of internalizing symptoms and parent-adolescent disagreements | Q78093622 | ||
| A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication | Q81093708 | ||
| Depression in children and adolescents | Q81146508 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 27-38 | |
| P577 | publication date | 2006-08-08 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Psychopharmacologic treatment of pediatric major depressive disorder | |
| P478 | volume | 191 |
| Q37892521 | Antidepressants and psychostimulants in pediatric populations: is there an association with mania? |
| Q42997861 | Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome |
| Q36690533 | Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study |
| Q29542530 | Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study |
| Q37912174 | Is it possible to improve neurodevelopmental abnormalities in Down syndrome? |
| Q37157631 | New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence? |
Search more.